Efficacy News and Research

RSS

Update on Nymox Pharmaceutical's Phase 3 program for NX-1207

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia. The most recent Safety Monitoring Committee meeting of April 30, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 indicated no significant safety concerns for the trials to date.

12 May 2010

Phase IIb study of EVP-6124 initiated in patients with Alzheimer's disease

EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimer's disease.

12 May 2010

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.

12 May 2010

Amorfix, Epitomics collaborate to develop high-affinity monoclonal antibodies against cancer targets

Amorfix Life Sciences and Epitomics, Inc. announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Amorfix has identified several disease specific epitopes (DSEs) on misfolded proteins with their proprietary ProMIS(TM) computational platform discovery technology, which will be used by Epitomics to generate highly specific monoclonal antibodies (mAbs).

11 May 2010

BSD, ProZyme partner to redefine biotherapeutic glycan analysis workflow

BioSystem Development, LLC (BSD) and ProZyme, Inc. announce a partnership to redefine biotherapeutic glycan analysis workflow. The first product from this collaboration combines ProZyme's proprietary enzymatic N-deglycosylation, labeling and cleanup chemistry with BSD's AssayMAP™ high- throughput micro chromatography platform resulting in a rapid, quantitative N-glycan sample preparation method fully enabled for any scale of automation.

11 May 2010

Gene variations may increase risk of developing schizophrenia: Study

By analyzing the genomes of patients with schizophrenia, genetics researchers have discovered numerous copy number variations—deletions or duplications of DNA sequences—that increase the risk of developing schizophrenia. Significantly, many of these variations occur in genes that affect signaling among brain cells.

11 May 2010

Transition Therapeutics reports increased revenue in third-quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended March 31, 2010.

11 May 2010

LifeWatch Services to unveil advanced AF TeleClinic service at HRS Annual Meeting

LifeWatch Services, Inc., a subsidiary of LifeWatch AG, will unveil its advanced AF TeleClinic service offering this week at the Heart Rhythm Society (HRS) Annual Meeting taking place in Denver, Colorado. The AF TeleClinic service, empowered with the latest communication, IT and medical technologies, ensures physicians are well equipped to deliver optimal diagnostic and treatment options to their patients.

11 May 2010

Forest, Almirall to present data on aclidinium bromide for COPD and LAS100977 for asthma at ATS conference

Forest Laboratories, Inc. and Almirall, S.A. today announced that they are presenting data from several studies of two investigational inhaled respiratory compounds at the annual American Thoracic Society International Conference taking place in New Orleans May 14-19, 2010. Data on aclidinium bromide, an inhaled muscarinic antagonist, which is in Phase III development for COPD, and LAS100977, a long-acting beta 2-agonist, in Phase II development for asthma, will be presented in 11 separate posters.

11 May 2010

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the first quarter ended March 31, 2010.

11 May 2010

Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010

Sucampo Pharmaceuticals, Inc. today announced the presentation of results from a phase 3 clinical trial investigating the use of lubiprostone in non-cancer pain patients with Opioid-induced Bowel Dysfunction (OBD). These results were the subject of an oral presentation at the Digestive Disease Week (DDW) 2010 conference in New Orleans, Louisiana, on May 5, 2010.

11 May 2010

Sucampo reports $0.3M net loss, $14.8M total revenue for first-quarter 2010

Sucampo Pharmaceuticals, Inc. today reported its consolidated financial results for the quarter ended March 31, 2010.

11 May 2010

BIOTRONIK launches TactiCath irrigated RF contact force ablation catheter for treating AF

BIOTRONIK SE & Co. KG, a leading manufacturer of implantable cardiac devices and pioneer of remote monitoring technologies today announced the market release of the TactiCath catheter. The TactiCath catheter, an Endosense company product, is an irrigated RF contact force ablation catheter with features that offer a major advance in ablation therapy for patients with cardiac arrhythmias and particularly Atrial Fibrillation (AF).

11 May 2010

Aastrom Biosciences reports third quarter 2010 FY results

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported financial results for its third fiscal quarter ended March 31, 2010, and also announced progress in its late-stage clinical development programs and corporate operations.

11 May 2010

Study results of CTT's Calmare Pain Therapy for CIPN to be presented

Competitive Technologies, Inc. announced today that Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit Virginia Commonwealth University's Massey Cancer Center, will present results of his study evaluating the treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy (CIPN) using CTT's Calmare® Pain Therapy Treatment.

10 May 2010

Endosense commences enrollment in EFFICAS I study with TactiCath force-sensing catheter

Endosense, a Swiss medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced it has enrolled the first patients in EFFICAS I, the first study of the EFFICAS series. These patients were enrolled in Na Homolce Hospital, Prague, Czech Republic and treated by Petr Neuzil, M.D. and Vivek Reddy, M.D.

10 May 2010

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Forest Laboratories, Inc. and Nycomed today announced that they will present data from six roflumilast posters during the American Thoracic Society (ATS) International Conference being held in New Orleans, LA, May 14 through May 19, 2010. Roflumilast is an investigational anti-inflammatory, oral medication for the treatment of Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis in patients at risk of exacerbations.

10 May 2010

Positive results from Cytori's Celution-based ADRC trial for treatment of no-option chronic heart disease patients

The first clinical trial of adipose (fat) tissue-derived stem and regenerative cells (ADRCs) for the treatment of no-option chronic heart disease patients showed the following: the procedure was safe and feasible; it demonstrated a statistically significant improvement in maximum oxygen consumption and patients' aerobic capacity measured as metabolic equivalents

10 May 2010

NIAMS, NINDS announce 5-year, $7.5M natural history study of Duchenne muscular dystrophy

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Institute of Neurological Disorders and Stroke (NINDS) are launching a five-year, $7.5 million natural history study of Duchenne muscular dystrophy (Duchenne), a degenerative genetically-linked neuromuscular disease. The study aims to validate non-invasive approaches to monitor the progression and treatment of Duchenne, and holds potential to facilitate the development of promising new therapies for people with the disease.

10 May 2010

Initiation of QVA149 Phase III clinical programme by Novartis triggers $7.5M milestone payment to Sosei

Sosei Group Corporation announce the commencement of the Phase III clinical programme by Novartis, with QVA149, a once-daily, dry powder bronchodilator for inhalation combining a fixed dose of the once-daily beta2-agonist QAB149 (indacaterol) and the long-acting muscarinic antagonist NVA237 (glycopyrronium bromide) for the treatment of chronic obstructive pulmonary disease (COPD). The start of Phase III triggers a $7.5m milestone payment to Sosei.

10 May 2010

Efficacy News and Research

Update on Nymox Pharmaceutical's Phase 3 program for NX-1207

Phase IIb study of EVP-6124 initiated in patients with Alzheimer's disease

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Amorfix, Epitomics collaborate to develop high-affinity monoclonal antibodies against cancer targets

BSD, ProZyme partner to redefine biotherapeutic glycan analysis workflow

Gene variations may increase risk of developing schizophrenia: Study

Transition Therapeutics reports increased revenue in third-quarter 2010

LifeWatch Services to unveil advanced AF TeleClinic service at HRS Annual Meeting

Forest, Almirall to present data on aclidinium bromide for COPD and LAS100977 for asthma at ATS conference

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010

Sucampo reports $0.3M net loss, $14.8M total revenue for first-quarter 2010

BIOTRONIK launches TactiCath irrigated RF contact force ablation catheter for treating AF

Aastrom Biosciences reports third quarter 2010 FY results

Study results of CTT's Calmare Pain Therapy for CIPN to be presented

Endosense commences enrollment in EFFICAS I study with TactiCath force-sensing catheter

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Positive results from Cytori's Celution-based ADRC trial for treatment of no-option chronic heart disease patients

NIAMS, NINDS announce 5-year, $7.5M natural history study of Duchenne muscular dystrophy

Initiation of QVA149 Phase III clinical programme by Novartis triggers $7.5M milestone payment to Sosei

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News